Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
296.8 DKK | +2.34% | +3.56% | -23.51% |
Apr. 12 | Chemometec A/S Reports Revenue for the Third Quarter and First Nine Months of 2023 -2024 | CI |
Apr. 12 | ChemoMetec A/S Provides Earnings Guidance for the Year 2023/24 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- With an expected P/E ratio at 37.69 and 32.17 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-23.51% | 724M | D | ||
+73.59% | 12.38B | B- | ||
-17.13% | 7.99B | C+ | ||
+16.67% | 7.21B | C- | ||
+3.57% | 5.79B | B | ||
+11.77% | 5.35B | D+ | ||
+29.65% | 4.63B | - | ||
-17.74% | 4.17B | B- | ||
-35.83% | 2.44B | C | ||
+3.09% | 2.03B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CHEMM Stock
- Ratings ChemoMetec A/S